# OnCo record black-diamond-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/black-diamond-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "black-diamond-therapeutics" ;
  schema:name "Black Diamond Therapeutics"@en ;
  schema:description "Black Diamond Therapeutics designs cancer pills that hit whole families of mutations in a growth protein at once. Its lead drug, silevertinib, targets mutated EGFR in lung cancer and brain tumours."@en ;
  schema:url <https://onco.cc/companies/black-diamond-therapeutics/>, <https://blackdiamondtherapeutics.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://blackdiamondtherapeutics.com/>, <https://blackdiamondtherapeutics.com/pipeline-programs/pipeline>, <https://www.sec.gov/Archives/edgar/data/1701541/000170154120000008/bdtx-exhibit991.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/glioblastoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/fgfr2/> ;
  onco:drugs <https://onco.cc/drugs/silevertinib/> ;
  onco:trials <https://onco.cc/trials/nct05256290/>, <https://onco.cc/trials/nct07326566/> .